Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
Something off on this page? Send us feedback.
Develops nature-derived psychedelic drug candidates centered on NPX-5 psilocybin-assisted psychotherapy for adjustment disorder after a cancer diagnosis. With no marketed product or revenue, it operates a small outsourced clinical-development model reliant on PsyLabs supply and intellectual property.
Develops nature-derived psychedelic drug candidates for palliative mental-health care, centered on NPX-5, a PsyLabs psilocybin capsule licensed for an Australian Phase IIb study in people with adjustment disorder after a cancer diagnosis. Separate substance-use-disorder psilocybin rights and an ibogaine supply option are licensed positions, not disclosed active clinical trials.
Operates with a small consultant-based team and outsources trial execution to Southern Star Research in Australia, where much of its clinical-development spending occurs. It has no registered products, marketed-product revenue, or separately reported business segments.
Depends on PsyLabs for NPX-5 supply and licensed intellectual property; PsyLabs is also its largest disclosed shareholder and an equity-method associate. The trial operates under Australian ethics, therapeutic-goods, import, and good-clinical-practice requirements.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Sep 30, 2025Cash & short-term investments $7.2M · Total debt $0 · Total assets $12.8M · Shareholders' equity $11.9M
- Revenue
- $0
- Operating income
- −$1.5M
- Net income
- −$753.3K
Reported in CAD, converted at the latest exchange rate
No dividends on record.
| Institutions2 holders · as of Mar 31, 2026 | ≥ 659.95% | 151.3K ADS | |
| Adds to | 659.95% |
22.9K ADS (1 ADS = 100 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (22.9K in the company's Sep 3, 2026 report, 19.0K elsewhere); stakes use the report.
Institutional filings for PBMWW (10,000% of the company) are not on file here, so the institutional figure is a floor.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
These groups come from separate filings that can overlap, so they add to 659.95%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Parallel Advisors, LLCInstitution | 659.56% | 151,250 ADS | 13Fas of Mar 31, 2026 |
Stonehage Fleming Financial Services Holdings LtdInstitution | 0.39% | 89 ADS | 13Fas of Mar 31, 2026 |
Psyence Labs Ltd.Strategic | —30.05% of class, as filed | — | 13Dfiled Jun 3, 2026 ↗ |
White Lion Capital, LLCStrategic | —8.93% of class, as filed | — | 13Gfiled Dec 13, 2024 ↗ |
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Compass Pathways (ADR)
Advanced synthetic-psilocybin rival in psychedelic mental health.
- Incannex Healthcare
Direct modality rival in psilocybin-assisted anxiety treatment.
- Helus Pharma
Next-generation serotonergic programs in depression and anxiety.
- XTL Biopharmaceuticals (ADR)
Nature-derived psychedelic API and manufacturing-platform rival.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Psyence Biomedical | $4.27 | −3.06% | $83.1K | — | — | — | — |
| Compass Pathways (ADR) | $13.21 | −0.11% | $1.79B | — | — | — | — |
| Incannex Healthcare | $3.27 | +0.93% | $39.1M | — | — | 587.3 | +1,566.7% |
| Helus Pharma | $12.12 | +1.44% | $740.7M | — | — | — | — |
| XTL Biopharmaceuticals (ADR) | $2.58 | −3.01% | $2.5M | — | — | — | — |
| Median | — | — | 587.3 | +1,566.7% |